Derivation of an iPSC line using the Sendai virus from a newborn boy with Alagille Syndrome.

We developed a well-characterized induced pluripotent stem cell (iPSC) line. This line was generated by reprogramming peripheral blood mononuclear cells from a male Alagille Syndrome baby using the Sendai viral method, which maintains genomic stability and pluripotent capacity. Markers of undifferentiated iPSCs were validated via immunocytochemistry. Trilineage potential was confirmed through immunofluorescent detection of lineage-specific markers (endoderm, mesoderm, ectoderm). Karyotypic analysis verified a normal diploid complement (46, XY). Additional assessments demonstrated Sendai virus clearance and absence of mycoplasma contamination. This iPSC line serves as a robust resource for disease modeling and regenerative medicine research.